Patient preferences for treating refractory overactive bladder in the UK

Hashim Hashim, Kathleen Beusterien, John F P Bridges, Kaitlan Amos, Linda Cardozo

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate patient preferences for refractory overactive bladder (OAB) treatments: sacral neuromodulation (SNM), onabotulinum toxin A (Botox®), and percutaneous tibial nerve stimulation (PTNS). Materials and methods: A cross-sectional Web survey was conducted with UK idiopathic OAB patients, recruited by a market research company. Preference was explored using direct questioning, comparing SNM, Botox, and PTNS, and via best–worst scaling (BWS). In BWS, patients prioritized subsets of 13 treatment characteristics (attributes) across 13 choice tasks, identifying the attribute they considered best and worst in each task. The attributes were those that were identified by patients in previous qualitative interviews as influential in treatment selection. BWS scores for each attribute, ranging from 1.0 (most favourable) to −1.0 (most unfavourable), were calculated based on the rates they were identified as best and as worst. To identify attributes that may influence treatment choice, BWS scores were compared among patients based on their most preferred treatment using analyses of variance; pairwise differences were assessed using Tukey’s multiple comparisons test. Results: The study population (N = 139) was 77 % female, had a mean age of 49 years, and were diagnosed a mean of 6.1 years ago. All 13 attribute BWS scores were viewed positively (score > 0.0) or negatively (score 

Original languageEnglish (US)
Pages (from-to)1619-1627
Number of pages9
JournalInternational Urology and Nephrology
Volume47
Issue number10
DOIs
StatePublished - Sep 7 2015

Fingerprint

Overactive Urinary Bladder
Patient Preference
Tibial Nerve
Therapeutics
Marketing
Analysis of Variance
Cross-Sectional Studies
Interviews
Population
onabotulinumtoxinA

Keywords

  • Botox
  • Onabotulinum toxin A
  • Patient preferences
  • Percutaneous tibial nerve stimulation
  • Refractory OAB treatment
  • Sacral neuromodulation

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Hashim, H., Beusterien, K., Bridges, J. F. P., Amos, K., & Cardozo, L. (2015). Patient preferences for treating refractory overactive bladder in the UK. International Urology and Nephrology, 47(10), 1619-1627. https://doi.org/10.1007/s11255-015-1100-3

Patient preferences for treating refractory overactive bladder in the UK. / Hashim, Hashim; Beusterien, Kathleen; Bridges, John F P; Amos, Kaitlan; Cardozo, Linda.

In: International Urology and Nephrology, Vol. 47, No. 10, 07.09.2015, p. 1619-1627.

Research output: Contribution to journalArticle

Hashim, H, Beusterien, K, Bridges, JFP, Amos, K & Cardozo, L 2015, 'Patient preferences for treating refractory overactive bladder in the UK', International Urology and Nephrology, vol. 47, no. 10, pp. 1619-1627. https://doi.org/10.1007/s11255-015-1100-3
Hashim, Hashim ; Beusterien, Kathleen ; Bridges, John F P ; Amos, Kaitlan ; Cardozo, Linda. / Patient preferences for treating refractory overactive bladder in the UK. In: International Urology and Nephrology. 2015 ; Vol. 47, No. 10. pp. 1619-1627.
@article{c8cec02bf9b347ccadd5480258119312,
title = "Patient preferences for treating refractory overactive bladder in the UK",
abstract = "Objective: To evaluate patient preferences for refractory overactive bladder (OAB) treatments: sacral neuromodulation (SNM), onabotulinum toxin A (Botox{\circledR}), and percutaneous tibial nerve stimulation (PTNS). Materials and methods: A cross-sectional Web survey was conducted with UK idiopathic OAB patients, recruited by a market research company. Preference was explored using direct questioning, comparing SNM, Botox, and PTNS, and via best–worst scaling (BWS). In BWS, patients prioritized subsets of 13 treatment characteristics (attributes) across 13 choice tasks, identifying the attribute they considered best and worst in each task. The attributes were those that were identified by patients in previous qualitative interviews as influential in treatment selection. BWS scores for each attribute, ranging from 1.0 (most favourable) to −1.0 (most unfavourable), were calculated based on the rates they were identified as best and as worst. To identify attributes that may influence treatment choice, BWS scores were compared among patients based on their most preferred treatment using analyses of variance; pairwise differences were assessed using Tukey’s multiple comparisons test. Results: The study population (N = 139) was 77 {\%} female, had a mean age of 49 years, and were diagnosed a mean of 6.1 years ago. All 13 attribute BWS scores were viewed positively (score > 0.0) or negatively (score ",
keywords = "Botox, Onabotulinum toxin A, Patient preferences, Percutaneous tibial nerve stimulation, Refractory OAB treatment, Sacral neuromodulation",
author = "Hashim Hashim and Kathleen Beusterien and Bridges, {John F P} and Kaitlan Amos and Linda Cardozo",
year = "2015",
month = "9",
day = "7",
doi = "10.1007/s11255-015-1100-3",
language = "English (US)",
volume = "47",
pages = "1619--1627",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "10",

}

TY - JOUR

T1 - Patient preferences for treating refractory overactive bladder in the UK

AU - Hashim, Hashim

AU - Beusterien, Kathleen

AU - Bridges, John F P

AU - Amos, Kaitlan

AU - Cardozo, Linda

PY - 2015/9/7

Y1 - 2015/9/7

N2 - Objective: To evaluate patient preferences for refractory overactive bladder (OAB) treatments: sacral neuromodulation (SNM), onabotulinum toxin A (Botox®), and percutaneous tibial nerve stimulation (PTNS). Materials and methods: A cross-sectional Web survey was conducted with UK idiopathic OAB patients, recruited by a market research company. Preference was explored using direct questioning, comparing SNM, Botox, and PTNS, and via best–worst scaling (BWS). In BWS, patients prioritized subsets of 13 treatment characteristics (attributes) across 13 choice tasks, identifying the attribute they considered best and worst in each task. The attributes were those that were identified by patients in previous qualitative interviews as influential in treatment selection. BWS scores for each attribute, ranging from 1.0 (most favourable) to −1.0 (most unfavourable), were calculated based on the rates they were identified as best and as worst. To identify attributes that may influence treatment choice, BWS scores were compared among patients based on their most preferred treatment using analyses of variance; pairwise differences were assessed using Tukey’s multiple comparisons test. Results: The study population (N = 139) was 77 % female, had a mean age of 49 years, and were diagnosed a mean of 6.1 years ago. All 13 attribute BWS scores were viewed positively (score > 0.0) or negatively (score 

AB - Objective: To evaluate patient preferences for refractory overactive bladder (OAB) treatments: sacral neuromodulation (SNM), onabotulinum toxin A (Botox®), and percutaneous tibial nerve stimulation (PTNS). Materials and methods: A cross-sectional Web survey was conducted with UK idiopathic OAB patients, recruited by a market research company. Preference was explored using direct questioning, comparing SNM, Botox, and PTNS, and via best–worst scaling (BWS). In BWS, patients prioritized subsets of 13 treatment characteristics (attributes) across 13 choice tasks, identifying the attribute they considered best and worst in each task. The attributes were those that were identified by patients in previous qualitative interviews as influential in treatment selection. BWS scores for each attribute, ranging from 1.0 (most favourable) to −1.0 (most unfavourable), were calculated based on the rates they were identified as best and as worst. To identify attributes that may influence treatment choice, BWS scores were compared among patients based on their most preferred treatment using analyses of variance; pairwise differences were assessed using Tukey’s multiple comparisons test. Results: The study population (N = 139) was 77 % female, had a mean age of 49 years, and were diagnosed a mean of 6.1 years ago. All 13 attribute BWS scores were viewed positively (score > 0.0) or negatively (score 

KW - Botox

KW - Onabotulinum toxin A

KW - Patient preferences

KW - Percutaneous tibial nerve stimulation

KW - Refractory OAB treatment

KW - Sacral neuromodulation

UR - http://www.scopus.com/inward/record.url?scp=84944150967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944150967&partnerID=8YFLogxK

U2 - 10.1007/s11255-015-1100-3

DO - 10.1007/s11255-015-1100-3

M3 - Article

C2 - 26347077

AN - SCOPUS:84944150967

VL - 47

SP - 1619

EP - 1627

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 10

ER -